Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy
Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy
复制标题
使用 Nivolumab 通过 ELISA 测量的晚期 RCC 患者血清 PD-1 水平升高：开发抗体治疗伴随诊断的新方法
DOI：
10.1007/s00432-018-2806-2
复制
发表时间：
2019
影响因子：
3.6
通讯作者：
Masafumi Ito
中科院分区：
文献类型：
--
作者：
Kosuke Mizutani;Kengo Horie;Taku Kato;Keita Nakane;Kyojiro Kawakami;Yasunori Fujita;Masafumi Ito
方法收集22例健康人、29例局限性肾细胞癌患者和20例初次诊断或复发时发现转移的肾细胞癌患者。使用人PD-1 ELISA试剂盒（Thermo Fisher Scientific，MA，USA）测定血清PD-1水平。对于基于Nivolumab的ELISA，将ELISA试剂盒中提供的识别PD-1的捕获抗体替换为由Ono pharmacology（Osaka，Japan）友好提供的Nivolumab。
MethodsAfter approval by the Review Board of Gifu University, 22 healthy individuals, 29 localized RCC patients and 20 RCC patients with metastasis found at initial diagnosis or at recurrence were studied. The serum PD-1 level was determined using human PD-1 ELISA kit (Thermo Fisher Scientific, MA, USA). For Nivolumab-based ELISA, the capture antibody recognizing PD-1 supplied in the ELISA kit was replaced with Nivolumab kindly provided by Ono pharmaceutical (Osaka, Japan).Results
DOI：
10.1016/s1470-2045(16)30406-5
发表时间：
2016-12
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Gibney GT;Weiner LM;Atkins MB
通讯作者：
Atkins MB